[HTML][HTML] Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
L Jiang, L Li, Y Liu, M Zhan, L Lu, S Yuan… - Frontiers in …, 2023 - frontiersin.org
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it
usually occurs following chronic liver disease. Although some progress has been made in …
usually occurs following chronic liver disease. Although some progress has been made in …
ETS transcription factors: Multifaceted players from cancer progression to tumor immunity
Y Wang, Z Huang, M Sun, W Huang, L Xia - Biochimica et Biophysica Acta …, 2023 - Elsevier
The E26 transformation specific (ETS) family comprises 28 transcription factors, the majority
of which are involved in tumor initiation and development. Serving as a group of functionally …
of which are involved in tumor initiation and development. Serving as a group of functionally …
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
Y Zhang, Y Zhang, H Tao, J Zhu, Y Lu, F Cheng… - Cancer Letters, 2023 - Elsevier
Lenvatinib is a standard therapy option for advanced hepatocellular carcinoma (HCC), but
resistance limits clinical benefits. In this study, we identified inhibition of ROS levels and …
resistance limits clinical benefits. In this study, we identified inhibition of ROS levels and …
[HTML][HTML] TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs
H Wang, F Chu, X Zhang, P Zhang, L Li… - Cell Death & …, 2023 - nature.com
The pregnane X receptor (PXR) is an important regulator of hepatocellular carcinoma
cellular resistance to antitumor drugs. Activation of PXR was modulated by the co-regulators …
cellular resistance to antitumor drugs. Activation of PXR was modulated by the co-regulators …
Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib
S Li, L Xu, G Wu, Z Huang, L Huang, F Zhang… - Advanced …, 2023 - Wiley Online Library
Tyrosine kinase inhibitors represented by sorafenib are the first‐line treatment for
hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a …
hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a …
[HTML][HTML] The transcription factor Ets1 influences axonal growth via regulation of Lcn2
M Gu, X Li, R Wu, X Cheng, S Zhou, X Gu - Molecular Neurobiology, 2024 - Springer
Transcription factors are essential for the development and regeneration of the nervous
system. The current study investigated key regulatory transcription factors in rat spinal cord …
system. The current study investigated key regulatory transcription factors in rat spinal cord …
pH-Responsive and Actively Targeted Metal–Organic Framework Structures for Multimodal Antitumor Therapy and Inhibition of Tumor Invasion and Metastasis
WL Jia, B Jin, WJ Xu, SW Liu, XY Mao… - … Applied Materials & …, 2023 - ACS Publications
Multimodal treatment is an important tool to overcome tumor drug resistance. The reactive
oxygen species (ROS) generated by photodynamic therapy (PDT) can directly play a killing …
oxygen species (ROS) generated by photodynamic therapy (PDT) can directly play a killing …
Single‐cell landscape of the cellular microenvironment in three different colonic polyp subtypes in children
Y Deng, C Li, L Huang, P Xiong, Y Li… - Clinical and …, 2024 - Wiley Online Library
Background The understanding of the heterogeneous cellular microenvironment of colonic
polyps in paediatric patients with solitary juvenile polyps (SJPs), polyposis syndrome (PJS) …
polyps in paediatric patients with solitary juvenile polyps (SJPs), polyposis syndrome (PJS) …
Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma
L Zhou, LH Mao, X Li, QL Wang, SY Chen… - Cancer …, 2023 - Wiley Online Library
Sorafenib is one a first‐line therapeutic drugs for advanced hepatocellular carcinoma
(HCC). However, only 30% of patients benefit from sorafenib due to drug resistance. We and …
(HCC). However, only 30% of patients benefit from sorafenib due to drug resistance. We and …
MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFβ pathway
R Ke, N Viswakarma, M Menhart, SK Singh, S Kumar… - Oncogene, 2024 - nature.com
Advanced hepatocellular carcinoma (HCC) is a lethal disease, with limited therapeutic
options. Mixed Lineage Kinase 3 (MLK3) is a key regulator of liver diseases, although its …
options. Mixed Lineage Kinase 3 (MLK3) is a key regulator of liver diseases, although its …